Transendocardial Autologous Bone Marrow Mononuclear Cell Injection in Ischemic Heart Failure
Author(s) -
Hans Fernando Rocha Dohmann,
Emerson C. Perin,
Christina Maeda Takiya,
Guilherme V. Silva,
Suzana A. Silva,
A Sousa,
Cláudio Tinoco Mesquita,
Maria-Isabel D. Rossi,
Bernardo M.O. Pascarelli,
Isabella Mariana de Assis,
Hélio S. Dutra,
João A.R. Assad,
Rodrigo V. Castello-Branco,
Cantidio Drummond,
Hans J.F. Dohmann,
James T. Willerson,
Radovan Borojević
Publication year - 2005
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.104.499178
Subject(s) - medicine , interventricular septum , adventitia , pathology , bone marrow , angiogenesis , cell therapy , heart failure , myocyte , perfusion , cardiology , cell , ventricle , genetics , biology
Cell-based therapies for treatment of ischemic heart disease are currently under investigation. We previously reported the results of a phase I trial of transendocardial injection of autologous bone marrow mononuclear (ABMM) cells in patients with end-stage ischemic heart disease. The current report focuses on postmortem cardiac findings from one of the treated patients, who died 11 months after cell therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom